Triple fixed combination for asthma patients

Bronchial asthma (BA) is one of the most common respiratory diseases. The primary purpose of BA treatment is to achieve disease control on a case-to-case basis. The disease control concept refers to not only the current control over symptoms, but also the risk of adverse outcomes in the future. Inhaled glucocorticosteroids (ICS) remain the mainstay of treatment for adult patients with AB. Long-acting e2-agonists (LABA) are recommended to all patients who continue to experience symptoms as add-on therapy to medium- or high-dose ICS as the preferred option for controlled treatment at stages 4 and 5. However, despite LABA / ICS therapy, some patients may still exhibit uncontrolled asthma, in which case long-acting anticholinergics (LAMA) should be included in the treatment regimen. Concurrent use of multiple and often different medications poses a significant burden for patients with BA. The presence of LABA / LAMA / ICS in a single inhaler can ensure the best medication adherence in patients with asthma. This therapy option is indicated for patients with persistent asthma uncontrolled with medium- or high-dose ICS + LABA and patients receiving medium- and high-dose ICS / LABA / tiotropium bromide in multiple inhalers. This will enhance BA control, which has been proven in a number of clinical studies. In the clinical case under discussion, a patient with severe BA had to be prescribed a disease-modifying drug in the form of a triple fixed-dose combination in a single inhaler to improve disease control, which led to increased tolerance of physical activities, absence of asthma attacks, shortness of breath, night symptoms, the need for short-acting e2-agonists (SABA), and calls for emergency medical service.

1. Sobko EA, Demko IV, Kraposhina AYu, Egorov SA, Vtyurina SS, Solov'eva IA et al. The level of adipocines in peripheral blood of young patients with bronchial asthma. Siberian Medical Review. 2015;94(4):29-33. (In Russ.) Available at: https://smr.krasgmu.ru/journal/84_n4__1_-15.pdf.

2. Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G et al. After asthma: redefining airways diseases. Lancet. 2O18;391(10118):350-40O. https://doi.org/10.1016/S0140-6736(17)30879-6.

3. Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015;11(1):14-24. https//doi.org/10.1183/20734735.008914.

4. Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled cor-ticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2018;199(12):1471-1477. https://doi.org/10.1164/rccm.201810-1868CI.

5. Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481-1490. https//doi.org/10.1016/j.rmed.2013.04.005.

6. Lee LA, Bailes Z, Barnes N, Boulet L-P, Edwards D, Fowler A et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69-84. https://doi.org/10.1016/S2213-2600(20)30389-1.

7. Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737-1749. https/doi.org/10.1016/S0140-6736(19)32215-9.

8. Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krull M, Salina A et al. Fixed-dose combination of jndacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase Illb, non-inferiority study (ARGON). Respir Med. 2020;170:106021. https//doi.org/10.1016/j.rmed.2020.106021.

9. van Boven JFM, Chapman KR. Triple Therapy of Asthma—Permutations and Combinations. J Allergy Clin Immunol Pract. 2022;10(11):2914-2915. https://doi.org/10.1016/j.jaip.2022.08.035.

10. Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63-72. https://doi.org/10.2147/JAA.S4214.

11. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396-407. https://doi.org/10.1183/09031936.00075614.

12. Greene G, Costello RW. Personalizing medicine - could the smart inhaler revolutionize treatment for COPD and asthma patients? Expert Opin Drug Deliv. 2019;16(7):675-677. https://doi.org/10.1080/17425247.2019.1628017.

13. Avdeev SN, Aisanov ZR. The new prospects of the inhalation therapy for bronchial asthma. Pulmonologiya. 2020;30(4):473-484. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-4-473-484.

14. Nenasheva NM. Triple combination: new approach to inhalation basic therapy of bronchial asthma. Practical Allergology. 2021;(2):40-53. (In Russ.) https://doi.org/10.46393/2712-9667_2021_2_40_53.

15. Blair HA. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma. Drugs. 2021;81(6):709-719. https://doi.org/10.1007/s40265-021-01518-w.

16. Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy. 2022;77(4):1105-1113. https://doi.org/10.1111/all.15076.

17. Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase A-M et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000-1012. https://doi.org/10.1016/S2213-2600(20)30190-9.

18. Derendorf H, Nave R, Drollmann A. Cerasoli F, Wurst W. Relevance of phar-macokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042-1050. https://doi.org/10.1183/09031936.00074905.

19. Cowie RL, Giembycz MA, Leigh R. Mometasonefuroate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin Pharmacother. 2009;10(12):2009-2014. https://doi.org/10.1517/14656560903078428.

20. Sanders MJ. Guiding inspiratory flow: development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017;2017:1495867. https://doi.org/10.1155/2017/1495867.

21. Altman P, Wehbe L, Dederichs J, Guerin T, Ament B, Moronta MC et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100. https://doi.org/10.1186/s12890-018-0662-0.

22. Usmani OS, Scichilone N, Mignot B, Belmans D, Van Holsbeke C, De Backer J et al. Airway deposition of extrafine inhaled triple therapy in patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations. Int J Chron Obstruct Pulmon Dis. 2020;15:2433-2440. https://doi.org/10.2147/COPD.S269001.

23. Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308-1331. https://doi.org/10.1183/09031936.00166410.

24. Iwanaga T, Kozuka T, Nakanishi J, Yamada K. Aerosol deposition of inhaled corticosteroids/long-acting e2-agonists in the peripheral airways of patients with asthma using functional respiratory imaging, a novel imaging technology. Pulmonary Therapy. 2017;3(1):219-231. https://doi.org/10.1007/s41030-017-0036-4.

25. Molimard M, Kottakis I, Jauernig J, Lederhilger S, Nikolaev I. Performance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting. Clin Drug Investig. 2021;41(5):415-424. https://doi.org/10.1007/s4O261-021-01021-wIF:3.2Q3.

26. Vaidya SS, Khindri S, Robinson J, Vaidya S, Khindri S, Robinson J et al. Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects. Eur Respir J. 2012;40(56):2145. Available at: https://erj.ersjournals.com/content/erj/40/Suppl_56/P2145.full.pdf

27. Buhl R, Tanase AM, Hosoe M, Cao W, Demin I, Bartels C et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. Pulm Pharmacol Ther. 2020;62:101919. https://doi.org/10.1016/j.pupt.2020.101919.

28. Чучалин АГ, Авдеев СН, Айсанов ЗР, Белевский АС, Васильева ОС, Геппе НА и др. Бронхиальная астма: клинические рекомендации. М.; 2021. 118 с. Режим доступа: https://spulmo.ru/upload/kr/BA_2021.pdf.